Effect of Sodium Glucose Cotransporter Inhibitors on Non Diabetic Fatty Liver Disease Patients
Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
Non-alcoholic fatty liver disease (NAFLD) has become a major health problem worldwide with an
increasing prevalence ranging from 13% in Africa to 42% in South-East Asia. The term NAFLD
includes a variety of diseases, ranging from liver fat deposition in more than 5% of
hepatocytes (steatosis-non-alcoholic fatty liver (NAFL)) to necroinflammation and fibrosis
(non-alcoholic steatohepatitis (NASH)), which can progress into NASH-cirrhosis, and
eventually to hepatocellular carcinoma 1 Lifestyle modifications remain the cornerstone of
NAFLD treatment, even though various pharmaceutical interventions are currently under
clinical trial. Among them, sodium-glucose co-transporter type-2 inhibitors (SGLT-2i) are
emerging as promising agents. Processes regulated by SGLT-2i, such as endoplasmic reticulum
(ER) and oxidative stress, low-grade inflammation, autophagy and apoptosis are all implicated
in NAFLD pathogenesis 2
In non-DM patients, only a small single center study exists which studied 12 patients under
dapagliflozin and 10 patients under teneligliptin, a DPP4 inhibitor, for a total of 12 weeks,
showing that after this intervention period, serum transaminases were decreased in both
groups, while in the dapagliflozin group, total body water and body fat decreased, leading to
decreased total body weight.3